<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7278987\results\search\testTrace\results.xml">
  <result pre="cases of COVID-19 viral pneumonia. Thus far, all evidence of" exact="treatment" post="options are derived from a few case experiences during"/>
  <result pre="extensively and shown to play a crucial role during viral" exact="infection" post="of the host cell. These enzymes are multifunctional and"/>
  <result pre="infections and thus may be of interest for future COVID-19" exact="treatment" post="strategies. In this review, we report an up-to-date description"/>
  <result pre="their regulatory mechanisms [14,15], PLPs are believed to contribute to" exact="infection" post="pathogenesis by using their intrinsic DUB and deISGylating activities"/>
  <result pre="enzymatic activities, other authors have demonstrated further effects on the" exact="infection" post="pathogenesis. The SARS-CoV PLP has been shown to complex"/>
  <result pre="translation of transforming-growth-factor (TGF)-Î²1 through ERK, which was inhibited by" exact="treatment" post="with MG132. Noticeably, the treatment with the ERK1/2 inhibitor"/>
  <result pre="ERK, which was inhibited by treatment with MG132. Noticeably, the" exact="treatment" post="with the ERK1/2 inhibitor U0126 inhibited the activation of"/>
  <result pre="should be evaluated as a possible therapeutic option for the" exact="treatment" post="of COVID-19. 3.2. PLPs Inhibition in In Vitro and"/>
  <result pre="attributable to ISG15 restoration, while the wild type PLP virus" exact="infection" post="resulted in more than 80% mortality [48]. The treatment,"/>
  <result pre="drugs are already used or under clinical evaluation for the" exact="treatment" post="of COVID-19. This includes the anti-malaria agent hydroxychloroquine, several"/>
  <result pre="reviewed [69]. In a recent report, molecular modeling and high-throughput" exact="screening" post="methods of 30,000 molecules were used to identify inhibitors"/>
  <result pre="evaluation of derivatives from Angelica keiskei leaves led to the" exact="isolation" post="of 9 chalcones and 4 coumarins, with inhibitory activity"/>
  <result pre="infections [80] and resveratrol has been found effective against MERS-CoV" exact="infection" post="in Vero E6 cells [81]. This could indicate that"/>
  <result pre="indicating a higher risk of COVID-19 in patients under chronic" exact="treatment" post="with immunosuppressive drugs has been reported, although several physicians"/>
  <result pre="would consider thiopurine analogs and their associated drugs for the" exact="treatment" post="of the cytokine storm in COVID-19, that could eventually"/>
  <result pre="cysteine protease, DUB and deISGylating activities that contribute significantly to" exact="infection" post="pathogenesis. The efficacy of targeting PLPs as an antiviral"/>
  <result pre="function of the whole protein. Thus, we suggest developing and" exact="testing" post="molecules with such capability [67], rather than focusing on"/>
  <result pre="in the fight against the current pandemic, the hypothesis of" exact="testing" post="the proposed drugs in COVID-19 should not be underestimated."/>
  <result pre="Pharm. Sin. B202010.1016/j.apsb.2020.02.00832292689 4.JinY.-H.CaiL.ChengZ.-S.ChengH.DengT.FanY.-P.FangC.HuangD.HuangL.-Q.HuangQ.et al.A rapid advice guideline for the" exact="diagnosis" post="and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia"/>
  <result pre="B202010.1016/j.apsb.2020.02.00832292689 4.JinY.-H.CaiL.ChengZ.-S.ChengH.DengT.FanY.-P.FangC.HuangD.HuangL.-Q.HuangQ.et al.A rapid advice guideline for the diagnosis and" exact="treatment" post="of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)Mil."/>
  <result pre="Liu Xing Bing Xue Za Zhi Zhonghua Liuxingbingxue Zazhi20204114515110.3760/cma.j.issn.0254-6450.2020.02.00332064853 9.LuH.Drug" exact="treatment" post="options for the 2019-new coronavirus (2019-nCoV)Biosci. Trends202014697110.5582/bst.2020.0102031996494 10.CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.A systematic"/>
  <result pre="review on the efficacy and safety of chloroquine for the" exact="treatment" post="of COVID-19J. Crit. Care202010.1016/j.jcrc.2020.03.005 11.ChenC.ZhangX.R.JuZ.Y.HeW.F.[Advances in the research of"/>
  <result pre="novel small molecule inhibitors against MERS-CoV papain-like protease via high-throughput" exact="screening" post="and molecular modelingBioorg. Med. Chem.2019271981198910.1016/j.bmc.2019.03.05030940566 71.SongY.H.KimD.W.Curtis-LongM.J.YukH.J.WangY.ZhuangN.LeeK.H.JeonK.S.ParkK.H.Papain-like protease (PLpro) inhibitory"/>
  <result pre="A Systematic Review and Meta-AnalysisAdv. Nutr.2016748849710.3945/an.115.01053827184276 81.LinS.-C.HoC.-T.ChuoW.-H.LiS.WangT.T.LinC.-C.Effective inhibition of MERS-CoV" exact="infection" post="by resveratrolBMC Infect. Dis.20171714410.1186/s12879-017-2253-828193191 82.KalusU.KiesewetterH.RadtkeH.Effect of CYSTUS052 and green"/>
  <result pre="CYSTUS052 and green tea on subjective symptoms in patients with" exact="infection" post="of the upper respiratory tractPhytother. Res. PTR2010249610010.1002/ptr.287619444821 83.KalusU.GrigorovA.KadeckiO.JansenJ.-P.KiesewetterH.RadtkeH.Cistus incanus"/>
  <result pre="tractPhytother. Res. PTR2010249610010.1002/ptr.287619444821 83.KalusU.GrigorovA.KadeckiO.JansenJ.-P.KiesewetterH.RadtkeH.Cistus incanus (CYSTUS052) for treating patients with" exact="infection" post="of the upper respiratory tract. A prospective, randomised, placebo-controlled"/>
  <result pre="the third epidemicLiver Transpl.202010.1002/lt.2575632196933 94.LiH.S.KuokD.I.T.CheungM.C.NgM.M.T.NgK.C.HuiK.P.Y.PeirisJ.S.M.ChanM.C.W.NichollsJ.M.Effect of interferon alpha and cyclosporine" exact="treatment" post="separately and in combination on Middle East Respiratory Syndrome"/>
 </snippets>
</snippetsTree>
